The BTD was granted based on the interim results of the Phase III DREAMM-7 trial, which met its primary endpoint.

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Bridgepoint slid on Friday after a group of 103 current and former employees and some related entities sold 14.7m shares in a placing. According to terms seen by Bloomberg, the shares were priced via ...

GSK plc (GSK, GSK.L) said that the Center for Drug Evaluation (CDE) of the National Medical Products Administration or NMPA in China ...

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

London open The FTSE 100 is expected to open 54 points higher on Tuesday, having closed up 0.07% on Monday at 8,278.44.

Find insight on GSK and more in the latest Market Talks covering the Health Care sector.

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...